Literature DB >> 33482351

Invadopodia: A potential target for pancreatic cancer therapy.

Yan Luo1, Jisheng Hu1, Yong Liu1, Le Li1, Yilong Li1, Bei Sun1, Rui Kong2.   

Abstract

Dissemination of cancer cells is an intricate multistep process that represents the most deadly aspect of cancer. Cancer cells form F-actin-rich protrusions known as invadopodia to invade surrounding tissues, blood vessels and lymphatics. A number of studies have demonstrated the significant roles of invadopodia in cancer. Therefore, the specific cells and molecules involved in invadopodia activity can provide as therapeutic targets. In this review, we included a thorough overview of studies in invadopodia and discussed their functions in cancer metastasis. We then presented the specific cells and molecules involved in invadopodia activity in pancreatic cancer and analyzed their suitability to be effective therapeutic targets. Currently, drugs targeting invadopodia and relevant clinical trials are negligible. Here, we highlighted the significance of potential drugs and discussed future obstacles in implementing clinical trials. This review presents a new perspective on invadopodia-induced pancreatic cancer metastasis and may prosper the development of targeted therapeutics against pancreatic cancer.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Invadopodia; Metastasis; Pancreatic cancer; Therapeutic targets

Mesh:

Year:  2021        PMID: 33482351     DOI: 10.1016/j.critrevonc.2021.103236

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  2 in total

1.  Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment.

Authors:  Kunpeng Wang; Xiongying Miao; Fanhua Kong; Siqi Huang; Jinggang Mo; Chong Jin; Yanwen Zheng
Journal:  Drug Des Devel Ther       Date:  2021-09-04       Impact factor: 4.162

2.  Silencing FYVE, RhoGEF, and PH domain containing 1 (FGD1) suppresses melanoma progression by inhibiting PI3K/AKT signaling pathway.

Authors:  Zehao Niu; Yan Li; Yujian Xu; Weiqian Jiang; Ran Tao; Youbai Chen; Yan Han
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.